Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.

Angiochem Inc.

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases.

Our partnership

AngioChem is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.

Contact

Bharat Srinivasa, Principal at Amplitude Venture Capital

Investment year: 2005
Industry sector: Drugs
Region: Quebec
Website
Follow Angiochem Inc.